Replimune Group (NASDAQ:REPL) Director Sells $408,500.00 in Stock

Replimune Group, Inc. (NASDAQ:REPL) Director Kapil Dhingra sold 21,500 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $19.00, for a total transaction of $408,500.00. Following the completion of the transaction, the director directly owned 21,669 shares of the company’s stock, valued at approximately $411,711. This represents a 49.80% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Replimune Group Trading Down 3.2%

Shares of NASDAQ:REPL opened at $20.02 on Friday. The company’s fifty day moving average price is $13.97 and its 200-day moving average price is $9.60. Replimune Group, Inc. has a one year low of $1.50 and a one year high of $21.26. The company has a debt-to-equity ratio of 0.59, a current ratio of 7.11 and a quick ratio of 6.90.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Wednesday, October 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.24. As a group, analysts anticipate that Replimune Group, Inc. will post -2.40 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. JPMorgan Chase & Co. lifted their price target on Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 26th. Weiss Ratings cut Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. Piper Sandler upgraded Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Replimune Group in a research report on Monday, October 5th. Finally, Leerink Partners raised their price objective on Replimune Group from $19.00 to $31.00 and gave the company an “outperform” rating in a report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $14.33.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors have recently made changes to their positions in the business. AXQ Capital LP increased its holdings in shares of Replimune Group by 4.1% in the second quarter. AXQ Capital LP now owns 27,121 shares of the company’s stock worth $300,000 after buying an additional 1,056 shares during the period. Walleye Capital LLC lifted its stake in shares of Replimune Group by 3.2% in the 1st quarter. Walleye Capital LLC now owns 71,592 shares of the company’s stock valued at $548,000 after acquiring an additional 2,192 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Replimune Group by 30.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,191 shares of the company’s stock valued at $223,000 after acquiring an additional 4,050 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Replimune Group in the 3rd quarter valued at about $64,000. Finally, Allworth Financial LP purchased a new stake in Replimune Group during the 2nd quarter valued at about $62,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.